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reas of negative charge come and go on the plasma 
membrane, report Tony Yeung, Sergio Grinstein (Hospital 
for Sick Children, Toronto, Canada), and colleagues. 
Loss of the charged areas correlates with the loss of certain 
signaling proteins from the membrane and inactivation of related 
downstream activity.
Attraction based on charge is well established for 
sequence-speciﬁ  c protein–protein interactions. But the Toronto 
group documented an electrostatic switch that was evident 
with many different probes, with many different anionic lipids, 
and on liposomes that lacked any proteins. The probes were 
modeled on fragments of the K-Ras protein and combined 
polycationic sequences with a hydrophobic anchor to keep 
the probe in the plasma membrane rather than interacting 
with the anionic nucleoplasm.
The probes were displaced from the intracellular face of the 
plasma membrane by three different conditions: an inﬂ  ux of cal-
cium; ﬂ  ipping out of negatively charged phosphatidylserine (PS); 
and the later stages of phagocytosis. Rac1 dissociated from phago-
somes with similar kinetics, even if locked in a GTP-bound form.
During phagocytosis, signaling results in hydrolysis of neg-
atively charged membrane-localized PIP2 to form uncharged 
diacylglycerol and cytoplasmic IP3. Inhibition of PIP2 hydroly-
sis reduced the loss of the probes from phagosomes.
The Toronto group suggests that charge-domi-
nated attachment may be reversed downstream of 
calcium elevation, PS ﬂ  ipping, and PIP2 hydrolysis 
for a wide range of biological pathways. “If it is 
happening in other contexts [such as around indi-
vidual receptor kinases] it would be much harder to 
tell,” says Grinstein, because of the smaller surface 
areas involved. But Grinstein will be looking next 
at endocytosis, based on evidence that endosomes 
and plasma membranes differ in their charge.
Reference: Yeung, T., et al. 2006. Science. 313:347–351. A probe detecting surface charge (red) is depleted during phagocytosis.
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How chronic stress exacerbates cancer
H
aving cancer is stressful enough 
without the knowledge that stress 
itself promotes tumor growth. But 
Premal Thaker, Liz Han, Aparna Kamat, 
Anil Sood (University of Texas M.D. 
Anderson Cancer Center, Houston, TX), 
and colleagues have found just that: human 
ovarian carcinoma cells injected into mice 
form tumors that grow more when the mice 
are exposed to chronic stress. Drugs that 
block stress responses may therefore be 
appropriate for certain cancer patients.
Humans and mice have two major re-
sponses to stress. The adrenal gland responds 
by producing glucocorticoids, and the 
sympathetic nervous system by producing 
catecholamines, which bind to the β adren-
ergic receptors ADRB1 and ADRB2. The 
Texan group identifi  ed a pathway leading 
from ADRB2 to protein kinase A (PKA) and 
the production of VEGF. VEGF is known to 
induce angiogenesis (the growth of new 
blood vessels) and thus to aid tumor growth.
The group had earlier found that pa-
tients with greater distress had higher 
levels of VEGF, and that catecholamines 
but not glucocorticoids were clearly 
linked in vitro to increased production of 
VEGF by cancer cells.
In the current study with the injected 
mice, they found that social isolation, 
2 hours of immobilization daily, or a β2 
agonist caused tumor nodule number and 
mean tumor weight to approximately 
double or triple. Levels of VEGF and 
mean vessel density in the tumors were 
both increased. All of these stress-
mediated increases were blocked 
by reducing the levels of ADRB2 
(but not ADRB1) or by antago-
nizing PKA or VEGF.
Only tumors that express 
ADRB2 will be susceptible to this 
particular stress pathway. It is not 
clear how large this universe is, as 
there have not been large-scale 
surveys of ADRB2 expression in 
different tumor types.
Patients with tumors that ex-
press high levels of ADRB2, 
and who have signifi  cant stressors such 
as surgery or lack of social support, 
would be the best candidates for a trial of 
β blockers as potential cancer therapeutics. 
These adrenergic receptor antagonists 
are widely used for hypertension, but 
may fi  nd a new application in reducing 
the negative effects of stress on tumor 
growth.
Reference: Thaker, P.H., et al. 2006. Nat. 
Med. doi:10.1038/nm1447.
Stress-dependent increases in vessel density (top, left 
to right) and tumor weight and number (bottom) are 
prevented by VEGF antagonist PTK787.
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